We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

103 hedge funds and large institutions have $200M invested in Aratana Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,479% more call options, than puts

Call options by funds: $442K | Put options by funds: $28K

74% more capital invested

Capital invested by funds: $115M → $200M (+$85.1M)

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

3% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 32

1% less funds holding

Funds holding: 104103 (-1)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
103
Holders Change
-1
Holders Change %
-0.96%
% of All Funds
2.24%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
33
Increased
33
Reduced
20
Closed
32
Calls
$442K
Puts
$28K
Net Calls
+$414K
Net Calls Change
+$125K

PETX Hedge Fund Activity: Q2 2019 in Review

103 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2019, worth a combined $200M — up 74% from $115M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PETX positions and 32 closed out — a net gain of 1 holder — while 33 added to existing stakes and 20 trimmed.

The largest buyer was Tudor Investment Corp, adding an estimated $14M. The largest seller was Engaged Capital, exiting entirely with an estimated $8.7M sold.

  • 103 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2019, down from 104 in Q1 2019.
  • Funds reported $200M of Aratana Therapeutics, Inc. stock for Q2 2019, up 74% quarter-over-quarter.
  • 33 funds opened new Aratana Therapeutics, Inc. positions in Q2 2019 and 32 closed out, a net change of +1 holder.
  • The largest Aratana Therapeutics, Inc. buyer in Q2 2019 was Tudor Investment Corp, an estimated $14M added.
  • The largest Aratana Therapeutics, Inc. seller in Q2 2019 was Engaged Capital, an estimated $8.7M sold.

Based on aggregated 13F filings for Q2 2019.